Stromal Therapeutics
Stromal Therapeutics is developing antibodies against novel stromal cell targets acting locally on the immune system to treat chronic immune-mediated diseases.
Stromal Therapeutics has raised €481k across 1 funding round from 1 investor, most recently a round in Feb 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Basel, Switzerland
Total raised
€481k
€481,371
Funding rounds
1
Investors
1
distinct backers
Active since
2022-02
latest 2022-02
Funding by year
EUR raised per yearStromal Therapeutics — funding by year — interactive chart.
Data table
| Stromal Therapeutics — funding by year | |
|---|---|
| 2022 | €481k |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-02-21 | Other | €481k | BaseLaunch | View deal → |
Investors
1Related news
- BaseLaunch invests USD 1.5 million in three new startupsstartupticker.ch · 2022-02
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData